

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 23, 2024**

**Corvus Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**001-37719**  
(Commission File Number)

**46-4670809**  
(I.R.S. Employer Identification No.)

**863 Mitten Road, Suite 102  
Burlingame, California 94010**  
(Address of Principal Executive Offices) (Zip Code)

**(650) 900-4520**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value \$0.0001 per share	CRVS	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Edith P. Mitchell, M.D., a director of Corvus Pharmaceuticals, Inc. has passed away.

**Item 8.01. Other Events.**

On January 23, 2024, Corvus Pharmaceuticals, Inc. issued a press release regarding the death of Dr. Mitchell, a copy of which is included as Exhibit 99.1 to this Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

Exhibit No.    Description

<a href="#">99.1</a>	<a href="#">Press release of Corvus Pharmaceuticals, Inc. dated January 23, 2024.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Corvus Pharmaceuticals, Inc.**

Date: January 23, 2024

By: /s/ Leiv Lea  
Leiv Lea  
Chief Financial Officer

## Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. The Company extends its condolences to her family, colleagues and community.

“Edith had a distinguished career in healthcare, spanning patient care, education, clinical research and improving health equity,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “She was a valued member of our Board and will be remembered for her keen insights, deep understanding of oncology and exemplary character and integrity.”

Dr. Mitchell served on the Corvus Board of Directors since September 2020 and had a trailblazing career in cancer care, research and the delivery of healthcare. She served in several positions at Thomas Jefferson University, including as a clinical professor, Department of Medicine and Medical Oncology at Sidney Kimmel Medical College and enterprise vice president for cancer disparities at Sidney Kimmel Cancer Center. She also held prominent roles with medical societies and cancer organizations, and was a retired United States Air Force Brigadier General where she was the first female physician ever to achieve this rank. Dr. Mitchell also served as President of the National Medical Association in 2015.

### About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Corvus plans to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit [www.corvuspharma.com](http://www.corvuspharma.com).

### INVESTOR CONTACT:

Leiv Lea  
Chief Financial Officer  
Corvus Pharmaceuticals, Inc.  
+1-650-900-4522  
[llea@corvuspharma.com](mailto:llea@corvuspharma.com)

### MEDIA CONTACT:

Sheryl Seapy  
Real Chemistry  
+1-949-903-4750  
[sseapy@realchemistry.com](mailto:sseapy@realchemistry.com)